| Stereochemistry | UNKNOWN |
| Molecular Formula | C14H16ClN3O4S2 |
| Molecular Weight | 389.878 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NS(=O)(=O)C1=CC2=C(NC(NS2(=O)=O)C3CC4CC3C=C4)C=C1Cl
InChI
InChIKey=BOCUKUHCLICSIY-UHFFFAOYSA-N
InChI=1S/C14H16ClN3O4S2/c15-10-5-11-13(6-12(10)23(16,19)20)24(21,22)18-14(17-11)9-4-7-1-2-8(9)3-7/h1-2,5-9,14,17-18H,3-4H2,(H2,16,19,20)
Cyclothiazide was presumably developed by Eli Lilly for the treatment of hypertension. It is believed that the drug, which belongs to the class of thiazide diuretics, exerts its action by inhibitin sodium reabsorption in the renal tubules. In 1993 it was discovered that cyclothiazide stimulates AMPA receptors thus inducing seizure behavior.
CNS Activity
Originator
Approval Year
Sourcing
PubMed
Patents
ACTIVE MOIETY
